COMPOSITIONS AND METHODS FOR NUCLEIC ACID MODIFICATIONS

NOVEL MULTISPECIFIC ANTIBODIES

CHIMERIC ANTIGEN RECEPTOR

ANTIGEN BINDING MOLECULES WITH INCREASED FC RECEPTOR BINDING AFFINITY AND EFFECTOR FUNCTION

BISPECIFIC ANTIBODY AND USE THEREOF

RAPAMYCIN RESISTANT CELLS

ENGINEERED IMMUNE CELLS WITH RECEPTOR SIGNAL STRENGTH MODULATED BY A HINGE

USES OF NK CELL ENGAGING ANTIBODY FUSION CONSTRUCTS FOR TREATMENTS

NOVEL ANTIGEN BINDING MOLECULE FORMATS

ANTI-BCMA CHIMERIC ANTIGEN RECEPTORS

HIDE1 COMPOSITIONS AND METHODS

MONOVALENT ANTI-MERTK ANTIBODIES AND METHODS OF USE THEREOF

PREPARATION AND APPLICATION OF CHIMERIC ANTIGEN RECEPTOR IMMUNE CELL CONSTRUCTED ON BASIS OF LOX1

CHIMERIC IMMUNOGLOBULIN

Antigen-binding polypeptide targeting B7H3 and application thereof

PROTEINS THAT BIND CD80 AND/OR CD86, AND OX40L

GPRC5D CHIMERIC ANTIGEN RECEPTORS AND CELLS EXPRESSING THE SAME

DOSING REGIMENS FOR PROTEIN THERAPEUTICS

PROMISCUOUS CD3 BINDING MOLECULES

ENGINEERED IMMUNE CELLS WITH RECEPTOR CROSS-TALK

COMPOSITIONS AND METHODS FOR T-CELL AND CYTOKINE ACTIVATION

MONOBODY-BASED CHIMERIC ANTIGEN RECEPTOR AND IMMUNE CELL INCLUDING SAME

DOUBLE SIDED CHIMERIC ANTIGEN RECEPTOR (CAR) ENGINEERED CELL MEMBRANE BASED DRUG DELIVERY SYSTEMS

Chimeric Antigen Receptor-Modified NK-92 Cells

mAb-DRIVEN CHIMERIC ANTIGEN RECEPTOR SYSTEMS FOR SORTING/DEPLETING ENGINEERED IMMUNE CELLS

PROTEINS BINDING HER2, NKG2D AND CD16

HLA BINDING VACCINE MOIETIES AND USES THEREOF

Chimeric Antigen Receptors with MAGE-A4 Specificity and Uses Thereof

FC-REGION VARIANTS WITH MODIFIED FCRN-BINDING PROPERTIES

IL-2 PROCYTOKINE ANTIBODY FUSION PROTEINS

POLYPEPTIDE LINKER FOR PREPARING MULTISPECIFIC ANTIBODIES

HETERODIMERIC ANTIBODY FC-CONTAINING PROTEINS AND METHODS FOR PRODUCTION THEREOF

BINDING MOLECULES THAT BIND CD137 AND PD-L1

Compositions and methods related to IL27 receptor binding

MULTITARGETING BISPECIFIC ANTIGEN-BINDING MOLECULES OF INCREASED SELECTIVITY

GP130 Binding Molecules and Methods of Use

IMMUNOCYTOKINES AND USES THEREOF

Universal anti-CD22 chimeric antigen receptor engineered immune cells

CD33 SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR CANCER IMMUNOTHERAPY

CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE

CONTORSBODY - A SINGLE CHAIN TARGET BINDER

IL12RB1-BINDING MOLECULES AND METHODS OF USE

ENHANCED CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF

BINDING AGENTS TARGETING TUMORS AND/OR IMMUNE CELLS

CD33 EXON 2 DEFICIENT DONOR STEM CELLS FOR USE WITH CD33 TARGETING AGENTS

HYBRID RECEPTORS WITH MULTIPLE TRANSCRIPTIONAL REGULATORS

BICISTRONIC CHIMERIC ANTIGEN RECEPTORS DESIGNED TO REDUCE RETROVIRAL RECOMBINATION AND USES THEREOF

COMPOSITIONS AND METHODS OF TREATING CANCER WITH CHIMERIC ANTIGEN RECEPTORS

MESOTHELIN-TARGETED CD40 AGONISTIC MULTISPECIFIC ANTIBODY CONSTRUCTS FOR THE TREATMENT OF SOLID TUMORS

ENGINEERED IMMUNE CELLS AND USES THEREOF

ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF

HLA BINDING VACCINE MOIETIES AND USES THEREOF

PROTEINS BINDING NKG2D, CD16, AND CEACAM5

FLT3L-BASED CHIMERIC PROTEINS

FAP BINDING MOLECULES AND USES THEREOF

Modified-IgG antibodies that bind transforming growth factor-β1 with high affinity, avidity and specificity

METHODS OF EXOGENOUS DRUG ACTIVATION OF CHEMICAL-INDUCED SIGNALING COMPLEXES EXPRESSED IN ENGINEERED CELLS IN VITRO AND IN VIVO

CHIMERIC ANTIGEN RECEPTORS TARGETING CD20

CHIMERIC ANTIGEN RECEPTOR (CAR) SPACER MODIFICATIONS ENHANCE CAR T CELL FUNCTIONALITY

HUMAN CD3 BINDING ANTIBODY

ASSEMBLY OF BISPECIFIC ANTIBODIES

ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY ANTIBODIES

Anti-PVRIG antibodies and methods of use

NOVEL CAR

VARIANT TARGET BINDING AGENTS AND USES THEREOF

TETRAVALENT ANTI-PSGL-1 ANTIBODIES AND USES THEREOF

METHODS OF USING BISPECIFIC MOLECULES HAVING IMMUNOREACTIVITY WITH PD-1 AND CTLA-4

A BISPECIFIC ANTIBODY TARGETING GPC3 AND CD47

Dual cytokine fusion proteins comprising IL-10

Dual cytokine fusion proteins comprising IL-10

Dual cytokine fusion proteins comprising IL-10

Dual cytokine fusion proteins comprising IL-10

Dual cytokine fusion proteins comprising IL-10

ENGINEERED ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF

ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF

COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS

MATERIALS AND METHODS FOR IMPROVED SINGLE CHAIN VARIABLE FRAGMENTS

ANTI-HtrA1 ANTIBODIES AND METHODS OF USE THEREOF

ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF

Dual cytokine fusion proteins comprising IL-10

Dual cytokine fusion proteins comprising IL-10

GLOBO SERIES ANTIGENS-BINDING CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF

NANOPARTICLE COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY

BISPECIFIC ANTIBODY FOR SPECIFICALLY NEUTRALIZING TGF-B SIGNAL OF HELPER T CELL, AND PHARMACEUTICAL COMBINATION AND USE THEREOF

BISPECIFIC ANTIBODY WHICH BINDS TO CD40 AND EpCAM

METHODS OF INDUCING IMMUNE TOLERANCE WITH MODIFIED ANTI-CD154 ANTIBODIES

Dual cytokine fusion proteins comprising IL-10

Dual cytokine fusion proteins comprising IL-10

Dual cytokine fusion proteins comprising IL-10

INDUCIBLE CHIMERIC ANTIGEN RECEPTOR AND APPLICATION THEREOF

EFFECTORLESS FC MOLECULES

Anti-ETEC adhesin protein antibodies and methods of use

METHODS OF NK CELL ENGINEERING TO ENHANCE TUMOR TARGETING

Modified B cells and methods of use thereof

Natural killer (NK) cell engagers binding to NKp46 and BCMA variants with Fc-engineering

MODIFIED IMMUNOGLOBULIN WITH AFFINITY FOR FcGAMMARIIb AND METHOD OF USE THEREOF

AGONISTIC ANTI-IL-2R ANTIBODIES AND METHODS OF USE

METHODS AND COMPOSITIONS FOR DEPLETING NATURAL KILLER CELLS AND USES THEREOF IN CELLULAR THERAPIES

CS1 TARGETED CHIMERIC ANTIGEN RECEPTOR-MODIFIED T CELLS

GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE

MODIFIED B CELLS AND METHODS OF USE THEREOF

ANTI-CD73 ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF

CANINIZED RAT ANTIBODIES TO CANINE INTERLEUKIN-31 RECEPTOR ALPHA

Bispecific antibody binding BCMA and CD3

HOMODIMERIC AND HETERODIMERIC PROTEINS COMPRISING BUTYROPHILIN

ANTI-cMET ANTIBODY

FC BINDING FRAGMENTS COMPRISING A PD-L1 ANTIGEN-BINDING SITE

CANINIZED ANTIBODIES TO CANINE INTERLEUKIN-31 RECEPTOR ALPHA

MULTISPECIFIC BINDING PROTEINS TARGETING CEA

SELECTIVE REDUCTION OF PROTEINS

MEANS AND METHODS FOR TREATING AND DIAGNOSING FIBROSIS OR FIBROSIS-ASSOCIATED DISEASES

COMPOSITIONS AND METHODS FOR T CELL ENGINEERING

CHIMERIC ANTIGEN RECEPTOR WITH MODIFIED HINGE REGION AND USES THEREOF

CHIMERIC ANTIGEN RECEPTORS FOR TREATMENT OF CANCER

HUMANIZED ANTIBODY SPECIFIC FOR CD22 AND CHIMERIC ANTIGEN RECEPTOR USING THE SAME

COMBINATION THERAPY WITH ANTI-PVRIG ANTIBODIES FORMULATIONS, ANTI-TIGIT ANTIBODIES, AND ANTI-PD-1 ANTIBODIES

CELL SECRETED MINIBODIES AND USES THEREOF

PROTEINS BINDING NKG2D, CD16 AND NECTIN4

TRISPECIFIC ANTI-CD38, ANTI-CD28, AND ANTI-CD3 BINDING PROTEINS AND METHODS OF USE FOR TREATING VIRAL INFECTION

FUSION PROTEIN CONTAINING ERYTHROPOIETIN POLYPEPTIDE

CHIMERIC ANTIGEN RECEPTORS (CARS) TARGETING NATURAL KILLER CELLS

CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR P95HER2 AND USES THEREOF

CHIMERIC ANTIGEN RECEPTORS TARGETED TO PSCA

BISPECIFIC ANTIBODY

Antibodies That Bind Human Cannabinoid 1 (CB1) Receptor

CHIMERIC ANTIGEN RECEPTOR TARGETING BCMA AND USE THEREOF

IGG4 HINGE-CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-1 (GPC1) FOR TREATING SOLID TUMORS

METHODS, THERAPIES AND USES FOR TREATING CANCER

ANTI-CD28 X ANTI-MSLN ANTIBODIES

COMPOSITION OF TRIAX ANTIBODIES AND METHOD OF MAKING AND USING THEREOF

Antigen binding molecule formats

CHIMERIC ANTIGEN RECEPTOR (CAR) WITH CD28 TRANSMEMBRANE DOMAIN

Vaccine Compositions and Antibodies For Lyme Disease

METHODS OF TREATING NEUTORPENIA USING G-CSF PROTEIN COMPLEX

INERT FORMAT

METHODS FOR THE USE OF A PD-1 X CTLA-4 BISPECIFIC MOLECULE

NUCLEIC ACIDS ENCODING A POLYPEPTIDE COMPRISING A MODIFIED FC REGION OF A HUMAN IGG1 AND AT LEAST ONE HETEROLOGOUS ANTIGEN

FORMULATIONS FOR PROTEIN THERAPEUTICS

COMBINATION THERAPY OF CANCER INVOLVING MULTI-SPECIFIC BINDING PROTEINS THAT BIND NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN

ANTI-PD1 ANTIBODIES AND THEIR USE AS THERAPEUTICS AND DIAGNOSTICS

ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY POLYPEPTIDES

IL10RB binding molecules and encoding nucleic acids

IL27RAlpha binding molecules and methods of use

Bispecific antibody

ANTI-CD3 ANTIBODY AND MOLECULES COMPRISING THE ANTIBODY

Heavy Chain Constant Regions with Reduced Binding to Fc Gamma Receptors

DUAL CAR-T CELLS

Interferon-gamma R2 (IFNGR2) binding molecules comprising single-domain antibodies and method of use thereof to treat autoimmune and inflammatory diseases

IL12 receptor synthetic cytokines and methods of use

LAG-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND LAG-3 ANTIGEN BINDING DOMAINS

IL10 agonists and methods of use thereof

CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF

IFNGR binding synthetic cytokines and methods of use

Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer, infections and autoimmune disorders

STEALTH CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF IN REDUCING CYTOTOXICITY TOWARDS NORMAL CELLS

Methods of treating neutorpenia using G-CSF protein complex

MODIFYING BINDING MOLECULES TO MINIMIZE PRE-EXISITING INTERACTIONS

ANTIBODIES AGAINST THE MUC1-C/EXTRACELLULAR DOMAIN (MUC1-C/ECD)

FC MUTANTS WITH MODIFIED FUNCTIONAL ACTIVITY

Universal chimeric antigen receptor T-cell preparation technique

RECOMBINANT HUMAN EPO-FC-FUSION PROTEINS WITH PROLONGED HALF-LIFE AND ENHANCED ERYTHROPOIETIC ACTIVITY IN VIVO

TREATMENT OF CD30-POSITIVE CANCER

T lymphocyte and use thereof

ANTI-CD28 COMPOSITIONS

CD22 BINDING MOLECULES AND USES THEREOF

Chimeric antigen receptors against multiple HLA-G isoforms

FELINE ANTIBODY VARIANTS FOR IMPROVING STABILITY

Agonistic anti-IL-2R antibodies and methods of use

CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF

METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS IN IGG4-RELATED DISEASES

PRODUCTION OF HETERODIMERIC PROTEINS

Anti-Tumor Associated Antigen Antibodies and Uses Thereof

BISPECIFIC HETERODIMERIC FUSION PROTEINS CONTAINING IL-15 - IL-15Ralpha Fc-FUSION PROTEINS AND IMMUNE CHECKPOINT ANTIBODY FRAGMENTS

Trispecific binding proteins, methods, and uses thereof

IMMUNE CELLS OVEREXPRESSING CELL SIGNALING REGULATORY FACTOR INTRODUCED FROM OUTSIDE AND USE THEREOF

PROTEINS BINDING NKG2D, CD16 AND 5T4

ENGINEERED ANTIBODIES

Dual EGFR-MUC1 Chimeric Antigen Receptor T Cells

BISPECIFIC T CELL ENGAGING ANTIBODY CONSTRUCTS

FC-REGION VARIANTS WITH IMPROVED PROTEIN A-BINDING

Elimination of BCMA-positive malignancies by CAR expressing NK cells

CD229 Car T Cells And Methods Of Use Thereof

BCMA BINDING MOLECULES AND METHODS OF USE THEREOF

CHIMERIC ANTIGEN RECEPTOR COMPRISING THIRD SIGNAL RECEPTOR AND USE THEREOF

ENGINEERED REGULATORY T CELL

CLDN18.2-TARGETING ANTIBODY, BISPECIFIC ANTIBODY AND USE THEREOF

MULTISPECIFIC ANTI-CLAUDIN-18.2 CONSTRUCTS AND USES THEREOF

HETERODIMERIC PROTEINS WITH FC MUTATIONS

FUSION PROTEIN COMPRISING PD-L1 PROTEIN AND USE THEREOF

HETERODIMERIC Fc FOR MAKING FUSION PROTEINS AND BISPECIFIC ANTIBODIES

MULTISPECIFIC ANTIBODIES AGAINST CD40 AND CD137

HUMAN CD47-TARGETING SINGLE-DOMAIN ANTIBODY AND USE THEREOF

FUSION ANTIBODY FOR PRESENTING ANTIGEN-DERIVED T CELL ANTIGEN EPITOPE OR PEPTIDE CONTAINING SAME ON CELL SURFACE, AND COMPOSITION COMPRISING SAME

PDE5 compositions and methods for immunotherapy

HOMODIMERIC PROTEIN CONSTRUCTS

IgE Antibody with Fcgamma Receptor binding

CHIMERIC ANTIGEN RECEPTOR AND IMMUNE EFFECTOR CELL EXPRESSING CHIMERIC ANTIGEN RECEPTOR

CHIMERIC ANTIGEN RECEPTORS AND RELATED METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER

NOVEL MULTISPECIFIC ANTIBODY FORMAT

MODIFIED CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE

PD-1 binding domains

Heterodimeric proteins for modulating gamma delta T cells

CHIMERIC ANTIGEN RECEPTOR TO WHICH ANTI-COTININE ANTIBODY IS LINKED, AND USE THEREOF

CHIMERIC ANTIGEN RECEPTOR

IMMUNOCYTOKINE COMPRISING HETERODYMERIC PROTEIN COMPLEX BASED ON IL-15/IL-15RA

A NOVEL ANTI-CD3/ANTI-EGFR BISPECIFIC ANTIBODY AND USES THEREOF

Antibodies specific for CD70 and their uses

TRUNCATED NKG2D CHIMERIC RECEPTORS AND USES THEREOF IN NATURAL KILLER CELL IMMUNOTHERAPY

Antibodies that bind to OX40 and their uses

PROTEINS COMPRISING CD3 ANTIGEN BINDING DOMAINS AND USES THEREOF

PEPTIDE-HINGE-FREE FLEXIBLE ANTIBODY-LIKE MOLECULE

Chimeric antigen receptor-modified NK-92 cells

RECOMBINANT MONOVALENT ANTIBODIES AND METHODS FOR PRODUCTION THEREOF

ANTI-IDIOTYPIC ANTIGEN BINDING MOLECULES AND METHODS OF USE THEREOF

FC VARIANTS WITH REDUCED EFFECTOR FUNCTION

METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS IN IGG4-RELATED DISEASES

TRANSGENE GENETIC TAGS AND METHODS OF USE

IGG ANTIBODY COMPOSITIONS AND METHODS OF MAKING THE SAME

TRUNCATED MULTIVALENT MULTIMERS

Dual cytokine fusion proteins comprising IL-10

Dual cytokine fusion proteins comprising IL-10

CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE

DEFINED COMPOSITION GENE MODIFIED T-CELL PRODUCTS

METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS

CD123 binding proteins and related compositions and methods

Immunologic effector cell of targeted CLD18A2, and preparation method and use thereof

scFv-Fc dimers that bind transforming growth factor-β1 with high affinity, avidity and specificity

CD3 BINDING MOLECULES

POLYPEPTIDE-FC CONJUGATE WITH ATTENUATED IMMUNE RESPONSE

DNMT3A KNOCKOUT CAR T CELLS FOR ADOPTIVE IMMUNOTHERAPY

Enhanced immune cells using dual shRNA and composition including the same

CONSTRUCTION OF CHIMERIC ANTIGEN RECEPTOR TARGETING CD20 ANTIGEN AND ACTIVITY IDENTIFICATION OF ENGINEERED T CELLS THEREOF

Dual cytokine fusion proteins comprising IL-10

HETERODIMERIC PROTEINS AND METHODS FOR PRODUCING AND PURIFYING THEM

RECOMBINANT IgG Fc MULTIMERS FOR THE TREATMENT OF IMMUNE COMPLEX-MEDIATED KIDNEY DISORDERS

ANTI-CD47/ANTI-PD-1 BISPECIFIC ANTIBODY, PREPARATION METHOD AND USE THEREOF

CD25 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF

Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof

CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-2

Modified-IgG antibodies that bind transforming growth factor-BETA1 with high affinity, avidity and specificity

Purification Method for Bispecific antigen-binding Polypeptides with Enhanced Protein L Capture Dynamic Binding Capacity

CHIMERIC PROTEINS IN AUTOIMMUNITY

PD-L1 BINDING PROTEINS COMPRISING SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CD8+ T CELL ANTIGENS

CAR FOR USE IN THE TREATMENT OF HVG DISEASE

TGF-beta TRAP

Chimeric antigen receptors against multiple HLA-G isoforms

Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof

Dual cytokine fusion proteins comprising IL-10

NK CELL COMPOSITIONS AND PREPARATIONS FOR IMMUNOTHERAPY AND METHODS FOR THEIR PRODUCTION

Dual cytokine fusion proteins comprising IL-10

Dual cytokine fusion proteins comprising IL-10

ANTI-CD47/ANTI-TIGIT BISPECIFIC ANTIBODY, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

POLYPEPTIDE COMPLEX FOR CONJUGATION AND USE THEREOF

COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS

CAR T-CELLS AGAINST BCMA FOR THE TREATMENT OF MULTIPLE MYELOMA

ANTI-CD47/ANTI-LAG-3 BISPECIFIC ANTIBODY, PREPARATION METHOD THEREFOR AND USE THEREOF

Long-Acting Therapeutic Fusion Proteins

Dual cytokine fusion proteins comprising IL-10

FLT3-specific chimeric antigen receptors and methods using same

ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF

MODIFIED ANTIBODY CONSTANT REGION

BISPECIFIC BINDING PROTEINS AND USES THEREOF

BIS(2-HALOACETAMIDO)-COMPOUNDS FOR USE AS LINKING AGENTS AND RESULTANT PRODUCTS WHICH COMPRISE ANTIBODIES, HALF-ANTIBODIES AND ANTIBODY FRAGMENTS

GHR-106 CHIMERIC ANTIGEN RECEPTOR CONSTRUCT AND METHODS OF MAKING AND USING SAME

ENGINEERING THE HINGE REGION TO DRIVE ANTIBODY DIMERIZATION

Antigen binding molecule formats

ICOS TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND ICOS ANTIGEN BINDING DOMAINS

Engineered immunoglobulin heavy chain-light chain pairs and uses thereof

ANTI-PD-L1/ANTI-LAG-3 MULTIPLE ANTIGEN BINDING PROTEINS AND METHODS OF USE THEREOF

Immunomodulatory antibodies

COMPOSITIONS AND METHODS FOR AUGMENTING ANTIBODY MEDIATED RECEPTOR SIGNALING

MÜLLERIAN INHIBITING SUBSTANCE TYPE 2 RECEPTOR (MISIIR)-SPECIFIC CAR T CELLS FOR THE TREATMENT OF OVARIAN CANCER AND OTHER GYNECOLOGIC MALIGNANCIES

Prostate cancer chimeric antigen receptors

Humanized antibody specific for CD22 and chimeric antigen receptor using the same

Antigen binding molecule formats

ENGINEERED NATURAL KILLER CELLS REDIRECTED TOWARD PURINERGIC SIGNALING, CONSTRUCTS THEREOF, AND METHODS FOR USING THE SAME

BINDING MOLECULES BINDING PD-L1 AND LAG-3

LAG-3 binding members

CELLS EXPRESSING A RECOMBINANT RECEPTOR FROM A MODIFIED TGFBR2 LOCUS, RELATED POLYNUCLEOTIDES AND METHODS

TARGETED DELIVERY OF IFN GAMMA USING ANTIBODY FUSION PROTEINS

Antibodies directed against T cell immunoglobulin and mucin protein 3 (TIM-3)

ANTI-SIRPalpha MONOCLONAL ANTIBODIES AND USES THEREOF

ENGINEERED ANTIBODIES

Heterodimeric antibodies that bind somatostatin receptor 2

Heterodimeric bispecific antibodies

Anti-MET antibodies and uses thereof

GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE

CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF

HIGH AFFINITY ENGINEERED T-CELL RECEPTORS TARGETING CMV INFECTED CELLS

GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE

FAB Molecules with a Rodent Hinge Region and a Non-Rodent CH1 Region

Notch receptors with hinge domain

FUSION PROTEINS HAVING MUTATED IMMUNOGLOBULIN HINGE REGION

Bispecific antibodies which bind blood coagulation factor VIII and have enhanced activity, and methods of use thereof for treating bleeding and associated conditions

AGONISTIC TRKB BINDING MOLECULES FOR THE TREATMENT OF EYE DISEASES

Bispecific anti-VEGF and anti-TrkB binding molecules for the treatment of eye diseases

Proteins binding NKG2D, CD16 and CLEC12A

Anti-CD28 compositions

ANTI-PD1 ANTIBODIES AND THEIR USE AS THERAPEUTICS AND DIAGNOSTICS

TETRAVALENT ANTI-PSGL-1 ANTIBODIES AND USES THEREOF